Should utilize comprehensive dietary records, biomarkers (such as inflammatory cytokines and gut microbiome profiles)

The gap

Evidence profile

Sourced from the future work and limitations of the source papers, classified as general, drawn from work published between 2025 and 2026, spanning 3 journals. Those papers have been cited 138 times in total.

Supporting evidence — 4 representative gaps

• The role of the gut–brain axis in the pathogenesis of depression and anxiety disorders: The significance of microbiota, bacterial metabolites, and vagus nerve signalling — A systematic review (2026) · Quality in Sport · doi

  Several priorities emerge for advancing the field from association toward clinically actionable knowledge. First, longitudinal and interventional human studies are needed to establish temporal precedence and causality, moving beyond the cross-sectional designs that dominate the current literature. Cohort studies that sample the microbiota, its metabolites, and psychiatric symptoms repeatedly over time—ideally spanning the transition into and out of episodes—would clarify whether microbial changes precede, accompany, or follow mood and anxiety symptoms. Second, methodological harmonisation is essential. The comparability of findings is currently undermined by variation in sequencing platforms and bioinformatic pipelines, in metabolite quantification methods, and in psychiatric outcome instruments. Adoption of standardised, absolute-quantification approaches to both microbiota and metabolites, together with consistent diagnostic and symptom-severity measures, would allow findings to be pooled meaningfully and would reduce the heterogeneity that presently limits meta-analysis (Xiong et al. 2025). Rigorous control for diet, body mass index, and medication—the dominant confounders— should be a standard requirement rather than an occasional refinement. Third, mechanistic specificity should be pursued through strain-resolved and metabolite-defined interventions. Rather than testing broad probiotic mixtures, future trials should evaluate defined strains selected for specified mechanistic properties—SCFA production, tryptophan handling, or vagal engagement—and should measure the corresponding mechanistic biomarkers alongside clinical outcomes, so that mechanism and effect are tested jointly. Engineered next-generation psychobiotics and precision prebiotics, designed to deliver defined metabolic functions, represent a natural extension of this approach. Fourth, patient stratification deserves explicit attention. If, as the evidence suggests, gut-derived inflammation drives depression in a definable subgroup, then trials enriched for such patients—identified by inflammatory and metabolite biomarkers—may reveal effects obscured in unselected samples. This stratified strategy aligns microbiota-targeted psychiatry with the broader movement toward precision medicine and may convert the currently modest average effect sizes into clinically meaningful benefits for the patients most likely to respond. Realising these priorities will require close interdisciplinary collaboration among psychiatry, gastroenterology, microbiology, immunology, and computational biology, since no single discipline commands all the methods the field demands. The integration of multi-omics data—linking metagenomic, metabolomic, immunological, and neuroimaging measures within the same participants—offers a particularly promising route to disentangling the causal architecture of the axis, and advances in machine learning may help identify the metabolite and microbial signatures most predictive of clinical outcome. Equally important is attention to the ecological validity of interventions: because diet is the single most powerful determinant of the microbiota, dietary context must be measured and, where possible, controlled in any trial of probiotics or prebiotics, lest a genuine effect be masked or a spurious one manufactured by uncontrolled nutritional variation. With these methodological foundations in place, the coming decade should be able to determine, for the first time with confidence, how large a role the gut–brain axis plays in human depression and anxiety and how best to act upon it.

  generalfuture work
  Keywords: microbiota metabolite mechanistic defined effect priorities field toward clinically first human metabolites psychiatric symptoms time
• The role of the gut–brain axis in the pathogenesis of depression and anxiety disorders: The significance of microbiota, bacterial metabolites, and vagus nerve signalling — A systematic review (2026) · Quality in Sport · doi

  Readers should therefore interpret the strength of the evidence conservatively: the convergence across independent lines of investigation is genuinely persuasive at the level of biological plausibility, but the quantitative magnitude of the microbiota's contribution to human depression and anxiety, and the reliability of microbiota-targeted treatments, remain to be established by larger, pre-registered, and methodologically harmonised studies.

  generallimitations
  Keywords: microbiota readers interpret strength evidence conservatively convergence across independent lines investigation genuinely persuasive level biological
• The relationship between physical activity and depression, anxiety, and stress in college students: a mediating effect of diet (2025) · Frontiers in Nutrition · cited 13× · doi

  should utilize comprehensive dietary records, biomarkers (such as inflammatory cytokines and gut microbiome profiles), and to develop multifaceted “food–nutrient– nutrient databases metabolome–mood” frameworks, thereby translating our findings into precise, tailored nutritional strategies for the enhancement of mental health.

  generalfuture work
  Keywords: nutrient utilize comprehensive dietary records biomarkers ammatory cytokines microbiome develop multifaceted food databases metabolome mood
• Understanding dysbiosis and resilience in the human gut microbiome: biomarkers, interventions, and challenges (2025) · Frontiers in Microbiology · cited 125× · doi

  Advancements in sequencing and multi-omics techniques, coupled with a decrease in sample analysis costs and increased available computational approaches, have resulted in the generation of large amounts of data. In the recovery of HGM, however, most longitudinal studies that have investigated microbiome compositional changes under the pressure of stressors have focused primarily on bacteria, and few studies have focused on alterations in bacteriophage, virus (Abeles et al., 2015; Górska et al., 2018; Modi et al., 2013; Sutcliffe et  al., 2023; Wang L. L. et  al., 2023), and eukaryotic (fungi and parasites) populations (Zimmermann and Curtis, 2019; Lamendella et al., 2018; Haak et al., 2021). This highlights the need to conduct more studies to investigate the mechanisms of RM, considering different domains of microorganisms. As with the current state of gut microbiome research, a critical gap persists in the availability of comprehensive multi-omics databases, specifically lacking databases encompassing microbial metagenomes, metabolites, transcriptomics, proteins, and lipids that can help to understate the mechanisms and biomarkers of resilient gut microbiomes. Following the Human Microbiome Project and numerous studies investigating the microbiome composition of healthy and unhealthy individuals, several databases focused on the human gut metagenome, all listed in Table 2 (Dai et al., 2022; Richardson et al., 2023; Forster et al., 2016; Proctor, 2016; Zhang et  al., 2021). While metagenomics is a powerful technique for studying the diversity and function of microbial communities in the gut, especially when some of them are unculturable, the presence of unmapped reads that are either due to novel taxa or

  generalfuture work
  Keywords: microbiome focused databases multi omics mechanisms microbial human advancements sequencing techniques coupled decrease sample costs

Questions about this gap